1. Home
  2. AKRO vs LMAT Comparison

AKRO vs LMAT Comparison

Compare AKRO & LMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • LMAT
  • Stock Information
  • Founded
  • AKRO 2017
  • LMAT 1983
  • Country
  • AKRO United States
  • LMAT United States
  • Employees
  • AKRO N/A
  • LMAT N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • LMAT Medical/Dental Instruments
  • Sector
  • AKRO Health Care
  • LMAT Health Care
  • Exchange
  • AKRO Nasdaq
  • LMAT Nasdaq
  • Market Cap
  • AKRO 2.1B
  • LMAT 2.0B
  • IPO Year
  • AKRO 2019
  • LMAT 2006
  • Fundamental
  • Price
  • AKRO $32.33
  • LMAT $94.88
  • Analyst Decision
  • AKRO Strong Buy
  • LMAT Buy
  • Analyst Count
  • AKRO 7
  • LMAT 7
  • Target Price
  • AKRO $43.20
  • LMAT $92.83
  • AVG Volume (30 Days)
  • AKRO 505.3K
  • LMAT 116.5K
  • Earning Date
  • AKRO 11-11-2024
  • LMAT 10-31-2024
  • Dividend Yield
  • AKRO N/A
  • LMAT 0.67%
  • EPS Growth
  • AKRO N/A
  • LMAT 49.21
  • EPS
  • AKRO N/A
  • LMAT 1.82
  • Revenue
  • AKRO N/A
  • LMAT $213,029,000.00
  • Revenue This Year
  • AKRO N/A
  • LMAT $15.09
  • Revenue Next Year
  • AKRO N/A
  • LMAT $9.19
  • P/E Ratio
  • AKRO N/A
  • LMAT $52.11
  • Revenue Growth
  • AKRO N/A
  • LMAT 14.81
  • 52 Week Low
  • AKRO $13.39
  • LMAT $47.33
  • 52 Week High
  • AKRO $37.00
  • LMAT $101.67
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 64.31
  • LMAT 62.88
  • Support Level
  • AKRO $30.13
  • LMAT $86.62
  • Resistance Level
  • AKRO $32.70
  • LMAT $90.82
  • Average True Range (ATR)
  • AKRO 1.42
  • LMAT 2.83
  • MACD
  • AKRO 0.11
  • LMAT 0.31
  • Stochastic Oscillator
  • AKRO 86.40
  • LMAT 60.01

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

About LMAT LeMaitre Vascular Inc.

LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.

Share on Social Networks: